LL-37 (Cathelicidin) vs Melanotan II

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

LL-37 (Cathelicidin)

LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.

Full details →

Melanotan II

Melanotan II is a synthetic peptide analog of α-MSH with broader receptor activity than Melanotan I. It produces tanning effects and has notable effects on sexual function and appetite suppression.

Full details →

Side-by-Side Comparison

AspectLL-37 (Cathelicidin)Melanotan II
MechanismDisrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects.Non-selective melanocortin receptor agonist affecting MC1R (tanning), MC3R and MC4R (sexual function and appetite). This broader activity explains its multiple effects beyond tanning.
Typical DosageResearch protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections.Typical protocols: 0.25-0.5mg daily during loading phase for 1-2 weeks, then 0.5-1mg before UV exposure for maintenance. Start low to assess tolerance.
AdministrationSubcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols.Subcutaneous injection. Usually combined with UV exposure for tanning effects. Nasal spray formulations exist but have lower bioavailability.
Side EffectsInjection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses.Nausea (common initially), facial flushing, spontaneous erections, increased libido, appetite suppression, and mole darkening.
Best For

Key Differences

Unique to LL-37 (Cathelicidin):

Unique to Melanotan II:

Ready to Learn More?